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Abstract 
Inflammation plays important roles in the pathogenesis of coxsackievirus B3 (CVB3)-induced acute viral myocarditis 
(AVMC). Ethyl pyruvate (EP) has been shown to be an anti-inflammatory agent. High mobility group box 1 (HMGB1)/
receptor for advanced glycation end product (RAGE)/nuclear factor (NF)-ΚB pathway has close relation with inflam-
matory responses. Here, we investigated the effects of EP on CVB3-induced AVMC and potential mechanisms. The 
mice with AVMC were treated with EP (40 or 80 mg/kg/day) from day 5 to day 7 post-infection. EP significantly 
decreased the mortality of mice with AVMC. H&E staining and immunohistochemistry for HMGB1 demonstrated less 
inflammatory lesions and fewer abnormal location of HMGB1 in the hearts of AVMC mice receiving EP. Immuoblot 
showed that EP significantly inhibited the levels of HMGB1, RAGE, phospho(p)-NF-ΚB and p-I-ΚBα, and raised I-ΚBα 
expression in the hearts of AVMC mice. Furthermore, real-time PCR and Elisa displayed decreased levels of HMGB1, 
TNF-α, IL-1β, IL-17 and increased levels of IL-10 in the hearts and serum of AVMC mice treated with EP. Our findings 
suggest that EP protects against CVB3-induced AVMC that is associated with inhibition of HMGB1/RAGE/NF-ΚB 
pathway.
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Background
Enteroviruses such as coxsackievirus B3 (CVB3) have 
been demonstrated to be the common causes of acute 
viral myocarditis (AVMC), which is characterized by 
myocardial inflammation (Kindermann et al. 2012; Cor-
sten et  al. 2012). Considerable attention has focused on 
treatment of this disease; however, no effective anti-
inflammatory therapy has been proven.
Ethyl pyruvate, which is a simple aliphatic ester of 
pyruvic acid, has been identified to play an important 
anti-inflammatory role in animal models. For example, 
recent evidences have demonstrated that ethyl pyruvate 
significantly decreased the mortality of the mice with 
lethal sepsis and acute lung injury (Ulloa et  al. 2002; 
Shang et al. 2009), and ameliorated severe acute pancrea-
titis (Yang et al. 2009). In the animal model of liver fail-
ure, ethyl pyruvate administration was found to improve 
hepatic histopathology and reduce the levels of inflam-
matory cytokines (Woo et  al. 2004). However, little is 
known whether ethyl pyruvate can inhibit CVB3-induced 
AVMC.
Substantial evidences have confirmed that the main 
anti-inflammatory mechanism of ethyl pyruvate is attrib-
uted to the inhibition of levels and secretion of high 
mobility group box 1 (HMGB1; Ulloa et al. 2002; Wang 
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et  al. 2013), which is an important pro-inflammatory 
cytokine in activation of inflammatory reaction. It is 
known that HMGB1 releases from nuclei into extracel-
lular milieu in response to exogenous and endogenous 
stimuli, subsequently, it binds to receptor for advanced 
glycation end products (RAGE), which is a known 
receptor for HMGB1, and then activates nuclear factor 
(NF)-ΚB to mediate the production and release of other 
cytokines, such as IFN-γ, TNF-α, IL-1β, IL-6, etc. (Ulloa 
and Messmer 2006; Xu et al. 2010).
In the present study, we evaluated whether ethyl pyru-
vate attenuated CVB3-induced AVMC via down-regu-
lation of HMGB1/RAGE/NF-ΚB pathway. Our results 
demonstrated that ethyl pyruvate significantly decreased 
mortality and reduced myocardial inflammation, which 
was closely associated with inhibition of HMGB1/RAGE/
NF-ΚB pathway in a murine model of AVMC.
Methods
Virus
CVB3 (Nancy strain), which was maintained by passage 
through Hela cells, was preserved in Key Laboratory of 
Viral Heart Diseases, Zhongshan Hospital. As our previ-
ous studies (Chen et al. 2011; Wang et al. 2014), the virus 
titer was measured by median tissue culture infective 
dose (TCID50).
Animals and animal model of AVMC
All animal protocols were approved by the Animal Care 
Committee of Fudan University. Male BALB/c mice 
(15–20 g), a susceptible mouse strain to CVB3 infection, 
were purchased from Shanghai SLAC Laboratory Animal 
Co., Ltd. According to our previous studies (Chen et al. 
2011; Xie et al. 2012), mice were intraperitoneally admin-
istrated with CVB3 that was diluted in 200  μl Eagle’s 
minimum essential medium (EMEM; TCID50 =  107) to 
establish AVMC. Sham-operated mice underwent the 
same procedure with intraperitoneal injection of 200  μl 
EMEM without CVB3.
Ethyl pyruvate preparation
Ethyl pyruvate (Sigma-Aldrich, USA) was dissolved in a 
Ringer’s lactate solution (RLS) (Tianrui Pharmaceutica, 
China).
Experimental protocol
In the experiment I, the mice which received CVB3 were 
randomly sacrificed on day 0, 1, 2, 3, 4, 5, 6, 7, 8 after the 
injection of CVB3 (n  =  12, each group). Inflammatory 
lesions in the hearts were detected.
In the second experiment, sham-operated mice and 
AVMC mice randomly received 200  μl RLS or 200  μl 
ethyl pyruvate (40 or 80 mg/kg/day) from day 5 to day 7 
post-infection (n = 12, each group). The mice were sacri-
ficed on day 8 post-infection, and hearts and serum were 
harvested. The mortality was recorded, and inflammatory 
lesions were determined. Furthermore, the expression 
and location of HMGB1, the levels of RAGE and phos-
pho (p)-NF-ΚB p65, NF-ΚB p65, p- IΚBα, IΚBα as well 
as cytokines (TNF-α, IL-1β, IL-17, IL-10) were measured.
Hematoxylin and eosin (H&E) staining
Paraffin-embedded hearts were cut into 5-μm-thick sec-
tions and detected inflammatory lesions by HE staining, 
as described in previous study (Wang et  al. 2014; Xie 
et al. 2012). Digital photographs were taken and analyzed 
using Image-Pro Plus 6.0 (Media Cybernetics, USA). The 
areas of inflammatory lesions were quantified and the 
extent of the lesions was expressed as the percentage of 
the area of positive area compared with the total area of 
the heart in the microscope field.
Immunohistochemistry
All procedures were conducted according to the instruc-
tion of immunohistochemistry assay kit (Boster, China). 
Endogenous peroxidase activity was blocked by incubat-
ing the slides in 3 % H2O2, and non-specific binding sites 
were blocked with 5  % bovine serum albumin (Sigma-
Aldrich, USA). Then, the sections were incubated with 
primary antibodies against HMGB1 (1:100, Abcam, UK) 
at 4  °C overnight followed by the secondary antibody 
provided by the kit. After that, the sections were devel-
oped in diaminobenzidine solution and counter-stained 
with hematoxylin.
Western blot
Mouse heart extracts were prepared for immunoblot-
ting as described (Xie et  al. 2012). Extracts were sepa-
rated by 10 % SDS-polycrylamide gel and transferred to 
a polyvinylidene fluorid membrane (Millipore, USA). The 
membranes were pre-incubated with bovine serum albu-
min for 1.5 h at room temperature to block endogenous 
immunoglobulins. The blots were then incubated with 
primary antibodies against HMGB1 (1:1000, Abcam, 
UK), RAGE (1:200, Boster, China) and phospho-NF-ΚB 
p65 (1:1000, Cell signaling technology, USA), NF-ΚB 
p65 (1:1000, Cell signaling technology, USA), phospho-
IΚBα(1:1000, Cell signaling technology, USA), IΚBα 
(1:1000, Cell signaling technology, USA) overnight at 
4  °C. Bound antibodies were detected with HRP-conju-
gated secondary antibody (1:8000, Jackson ImmunoRe-
search, USA) for 1.5  h at room temperature, followed 
by development using Super-signal West Pico Chemilu-
minescence detection system (Thermo Scientific, USA). 
β-actin (1:4000, KangChen Biotech, China) was used as 
the internal control. The levels of target molecules were 
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analyzed by densitometry using Image Lab Software 
(Bio-Rad, USA). The levels of RAGE and IΚBα were 
expressed as ratio of the intensity of target bands to that 
of β-actin band, and phosphorylation of NF-ΚB p65 and 
IΚBα was quantified as ratio of the intensity of phospho-
NF-ΚB p65 to that of NF-ΚB p65 and ratio of the inten-
sity of phospho-IΚBα to that of IΚBα, respectively.
RNA isolation and real‑time polymerase chain reaction 
(PCR)
Total RNA was extracted from mouse hearts using Trizol 
(Invitrogen, USA) with the ratio of A260–A280 at 1.8–2.0 
levels. 500 ng RNA per sample was used for reverse tran-
scription and PCR assay (Takara, Japan). The primers used 
for PCR include (McClellan et  al. 2015): HMGB1 sense 
primer: 5′-TGGCAAAGGCTGACAAGGCTC-3′, anti-
sense primer: 5′-GGATGCTCGCCTTTGATTTTGG-3′; 
TNF-α sense primer: 5′-ACCCTCACACTCAGATCAT 
CTT-3′, anti-sense primer: 5′-GGTTGTCTTTGAGA-
TCCATGC-3′; IL-1β sense primer: 5′-CGCAGCAGCA-
CATCAACAAGAGC-3′, anti-sense primer: 5′-TGTC 
CTCATCCTGGAAGGTCCACG-3′; IL-17 sense primer: 
5′-ACCTCACACGAGGCACAAGT-3′, anti-sense primer: 
5′-AGCAGCAACAGCATCAGAGAC-3′; IL-10 sense 
primer: 5′-GCACTACCAAAGCCACAAG-3′, anti-sense 
primer: 5′-CAGTAAGAGCAGGCAGCATA-3′; β-actin 
sense primer: 5′-GATTACTGCTCTGGCTCCTAGC-3′, 
anti-sense primer: 5′-GACTCATCGTACTCCTGCTTG 
C-3′. And procedures were carried out as follows: hold-
ing stage (denaturation) at 95  °C for 30  s, cycling stage 
including annealing at 95 °C for 5 s and extension at 60 °C 
for 34 s which was replicated 40 cycles. All reactions were 
conducted by duplicate for each sample and performed in 
Applied Biosystem®7500 Real-Time PCR System. The data 
were analyzed using comparative CT method.
Enzyme‑linked immunosorbent assay (ELISA)
According to the manufacturer’s instructions, the levels 
of HMGB1, TNF-α, IL-1β and IL-17 in the serum were 
detected using ELISA kits specific for mice (Uscn Life 
Science Inc, China), and serum IL-10 was assessed using 
a mouse IL-10 ELISA kit (R&D Systems, USA). The sensi-
tivities for HMGB1, TNF-α, IL-1β, IL-17 and IL-10 were 
22.54, 6, 2.7, 6.3 and 1.97 pg/ml, respectively. All samples 
were measured in triplicate.
Statistical analysis
All analyses were carried out with SPSS16.0 statisti-
cal package (SPSS Inc, Chicago, IL). All data were 
shown as mean ±  SEM. The comparisons of multiple 
groups were analyzed by one-way ANOVA with post 
hoc least significant difference (LSD) test. In the mor-
tality study, time-to survival data were analyzed by the 
Kaplan–Meier method and compared with the log-
rank test.
Results
The changes of inflammatory lesions in the myocardium 
after CVB3 infection
The mice which received CVB3 were randomly sacrificed 
everyday within 8 days after CVB3 infection as described 
in methods, and inflammatory lesions in the hearts were 
measured. As demonstrated in previous study, inflamma-
tory areas have been recognized as the pathological char-
acteristic of viral myocarditis (Kindermann et  al. 2012). 
H&E staining demonstrated inflammatory lesions were 
completely absent from the 1st day to the 4th day after 
CVB3 injection, while inflammatory areas were increas-
ingly increased from the 5th day to the 8th day after 
infection (P < 0.05; Fig. 1).
Ethyl pyruvate decreases the mortality of AVMC mice 
and reduces inflammatory lesions in the hearts of mice 
with AVMC
To assess whether ethyl pyruvate treatment could 
improve AVMC, ethyl pyruvate at the dose of 40 or 
80 mg/kg/day was administrated from the 5th day to the 
7th day after CVB3 infection. As demonstrated in Fig. 2, 
the increase of mortality in AVMC mice was decreased 
by ethyl pyruvate in a dose-dependent manner (Fig.  2). 
Moreover, H&E staining demonstrated that the AVMC 
mice receiving ethyl pyruvate had a dramatic reduc-
tion of inflammatory lesions in the hearts, as compared 
with the AVMC mice treated with RLS (P < 0.01; Fig. 3). 
Inspiringly, high dose of ethyl pyruvate showed more 
effect in decreasing inflammatory lesions than low dose 
of ethyl pyruvate (P < 0.01; Fig. 3). These data implies that 
ethyl pyruvate significantly attenuates AVMC in a dose-
dependent pattern.
Ethyl pyruvate treatment inhibits the expression 
and release of HMGB1 in AVMC mice
Ethyl pyruvate has been recognized as a pharmacologi-
cal inhibitor of HMGB1 (Ulloa et  al. 2002; Shang et  al. 
2009; Yang et al. 2009). To investigate the effect of ethyl 
pyruvate on HMGB1 expression in the mice with AVMC, 
the expression of HMGB1 in the hearts of AVMC mice 
treated with 80  mg/kg/day of ethyl pyruvate was deter-
mined by real-time PCR and western blot. When com-
pared to sham mice, HMGB1 expression was significantly 
elevated in the hearts of AVMC mice; however, the pres-
ence of ethyl pyruvate dramatically decreased HMGB1 
levels in the hearts of mice with AVMC (P  <  0.001; 
Fig. 4a, b).
Immunohistochemistry for HMGB1 was performed 
to assess whether ethyl pyruvate altered the localization 
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of HMGB1 in the hearts of AVMC mice. As shown in 
Fig. 4c, HMGB1 was predominantly located in the nuclei 
of the cells in the hearts of sham mice, whereas HMGB1 
was not only positive in the nuclei but also positive in 
the cytoplasm of the cells and extracellular milieu in the 
hearts of AVMC mice. This results suggested that CVB3 
induced HMGB1 translocation from nuclei to cytoplasm 
and extracellular milieu in the hearts, which is consistent 
with the characteristics of HMGB1 release. As expected, 
when compared to AVMC mice treated with RLS, posi-
tive staining for HMGB1 in cytoplasm and extracellu-
lar milieu was significantly decreased in AVMC mice 
treated with ethyl pyruvate (Fig. 4c), indicating that ethyl 
pyruvate inhibited release of HMGB1 in the hearts of 
Fig. 1 The changes of inflammatory lesions in the myocardium after CVB3 infection. The mice were sacrificed on day 0, 1, 2, 3, 4, 5, 6, 7, 8 after CVB3 
injection, and the hearts were harvested. a A representative HE staining for inflammatory lesions in the heart tissues (×200, arrow). b Quantification 
of inflammatory lesions. Data were shown as mean ± SE from 6 to 12 individual experiments. *P < 0.05 versus day 0 after infection. **P < 0.05 versus 
day 5 after infection. #P < 0.01 versus day 6 after infection. ##P < 0.01 versus day 7 after infection
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AVMC mice. Moreover, the levels of HMGB1 in serum 
were evaluated by ELISA. As shown in Fig. 4d, in com-
parison with sham mice, significant increase of HMGB1 
was detected in the serum of AVMC mice (P  <  0.001). 
However, serum HMGB1 in AVMC mice was reduced by 
ethyl pyruvate treatment (P < 0.01; Fig. 4d).
These evidences confirm that ethyl pyruvate treatment 
inhibits the expression and release of HMGB1 in the 
mice with AVMC.
Ethyl pyruvate suppresses the expression of RAGE 
and activation of NF‑ΚB pathway in the mice with AVMC
It is well known that HMGB1 binds to its receptors, such 
as RAGE, and then activates NF-ΚB to increase the pro-
duce and release of inflammatory cytokines (Ulloa and 
Messmer 2006). In other word, pro-inflammatory effect 
of HMGB1 depends on the activation of downstream 
inflammatory signaling pathway. To further address 
the mechanism that ethyl pyruvate improved AVMC, 
the levels of RAGE, phospho-NF-ΚB p65, NF-ΚB p65, 
phospho-IΚBα and IΚBα were detected using western 
blot as described in methods. When compared to sham 
mice, RAGE expression was significantly elevated in the 
hearts of AVMC mice (P  <  0.01). Nevertheless, ethyl 
pyruvate markedly decreased RAGE expression in the 
mice with AVMC (P  <  0.05; Fig.  5a, b). Moreover, the 
levels of phospho-NF-ΚB p65 and phospho-IΚBα were 
obviously increased in AVMC mice (P  <  0.01); how-
ever, the presence of ethyl pyruvate reduced phospho-
NF-ΚB p65 and phospho-IΚBα (P  <  0.05; Fig.  5a, c, d). 
In contrast with an increase in phospho-NF-ΚB p65 and 
phospho-IΚBα, the expression of IΚBα was substantially 
deceased in AVMC mice, which was recovered by ethyl 
pyruvate (P < 0.05; Fig. 5a, e). These results indicated that 
in the mice with AVMC, ethyl pyruvate treatment could 
reduce RAGE expression and inhibit activation of NF-ΚB 
by down-regulation of phosphorylation of IΚBα and sup-
pression of degration of IΚBα.
Activation of NF-ΚB mediates the production and 
release of many cytokines, such as TNF-α, IL-1β, IL-17 
and IL-10 (Xu et al. 2010; Kwok et al. 2012; Lutay et al. 
2014). And previous studies have reported that these 
cytokines are involved in the progression of CVB3-
induced acute viral myocarditis (Kindermann et al. 2012; 
Xie et  al. 2011). Therefore, the levels of TNF-α, IL-1β, 
IL-17 and IL-10 were determined by real-time PCR and 
Elisa as described in methods. These results demon-
strated that compared to sham mice, the levels of TNF-
α, IL-1β, IL-17 and IL-10 were substantially elevated in 
the hearts and serum of AVMC mice (P < 0.001; Fig. 6). 
However, the presence of ethyl pyruvate significantly 
decreased the levels of TNF-α, IL-1β, IL-17 and increased 
the expression of IL-10 in the hearts and serum of AVMC 
mice (P < 0.01; Fig. 6), indicating that ethyl pyruvate ther-
apy could down-regulate pro-inflammatory cytokines 
(TNF-α, IL-1β, IL-17) and raise anti-inflammatory 
cytokine (IL-10) in the hearts and serum of AVMC mice.
Together, these observations support that ethyl pyru-
vate reduces the expression of RAGE and suppresses acti-
vation of NF-ΚB pathway in the mice with AVMC.
Discussion
The present study demonstrates for the first time that 
ethyl pyruvate treatment protects from CVB3-induced 
AVMC in animal model, as indicated by the facts that 
ethyl pyruvate significantly decreases mortality and 
reduces inflammatory lesions in the hearts of AVMC 
mice. Our findings also confirm that ethyl pyruvate treat-
ment markedly decreases the expression and release of 
HMGB1, down-regulates the levels of RAGE, p-NF-ΚB 
p65 and p-IΚBα, and raises the expression of IΚBα in 
hearts of AVMC mice. In addition, ethyl pyruvate reduces 
the levels of pro-inflammatory cytokines (TNF-α, IL-1β, 
IL-17) and elevates the expression of anti-inflammatory 
cytokine (IL-10). These findings suggest that ethyl pyru-
vate may improve CVB3-induced AVMC, which may be 
closely associated with the reduction of HMGB1/RAGE/
NF-ΚB pathway.
Ethyl pyruvate, a simple aliphatic ester derived from 
pyruvic acid, has been shown to be an effective anti-
inflammatory agent in a variety of inflammatory diseases 
including severe sepsis, autoimmune hepatitis, severe 
acute pancreatitis (Ulloa et  al. 2002; Shen et  al. 2014; 
Luan et al. 2013). In this study, we showed that compared 
Fig. 2 Effect of ethyl pyruvate (EP) on mortality of the mice with 
AVMC. The sham mice and AVMC mice were intraperitoneally admin-
istrated with Ringer’s lactate solution (RLS) or EP (40 or 80 mg/kg/
day) from the 5th day to the 7th day post-infection. *P < 0.05 versus 
AVMC + RLS
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to the AVMC mice treated with RLS, the AVMC mice 
receiving ethyl pyruvate treatment from day 5 to day 
7 after CVB3 injection had lower mortality and fewer 
inflammatory lesions in the hearts in a dose-dependent 
manner, suggesting that ethyl pyruvate could improve 
AVMC.
HMGB1, a nonhistone nuclear protein, is released 
from nuclei into extracellular milieu, and acts as a 
cytokine-like mediator in many inflammatory diseases, 
such as sepsis, rheumatoid arthritis (Wang et  al. 1999; 
Shi et al. 2012). HMGB1 was up-regulated in the hearts 
and serum of the mice with MHCα-induced myocarditis, 
which was associated with increased myocardial inflam-
mation (Su et al. 2011). In consistent with previous study, 
our findings also displayed elevated expression and 
release of HMGB1 in AVMC mice. Mounting evidences 
have shown that treatment with HMGB1 inhibitors 
such as ethyl pyruvate is beneficial in many inflamma-
tory diseases (Musumeci et al. 2014). Ethyl pyruvate, as 
the first described pharmacological inhibitor of HMGB1 
secretion, has the ability to specific interference with 
HMGB1 release from the nuclei to extracellular milieu 
(Ulloa and Messmer 2006). Meanwhile, ethyl pyruvate 
has also been reported to decrease the expression of 
HMGB1 (Lee et  al. 2013). As demonstrated in a recent 
study, ethyl pyruvate treatment showed a significant 
decrease in HMGB1 levels that was correlated with 
improved lethality in the mice with sepsis (Ulloa et  al. 
2002). In TDI-induced asthma, ethyl pyruvate reduced 
the expression and release of HMGB1, which was in line 
with obvious improvement in neutrophil infiltration into 
the airway (Tang et al. 2014). Our present study revealed 
Fig. 3 Effect of ethyl pyruvate (EP) on inflammatory lesions in heart tissues of CVB3-induced AVMC. The sham mice and AVMC mice were 
intraperitoneally administrated with Ringer’s lactate solution (RLS) or EP (40 or 80 mg/kg/day) from the 5th day to the 7th day post-infection. a A 
representative HE staining for inflammatory lesions in the heart tissues (×200, arrow). b Quantification of inflammatory lesions. Data were shown as 
mean ± SE from 6 to 12 individual experiments. *P < 0.01 versus Sham + RLS. #P < 0.01 versus AVMC + RLS. $P < 0.01 versus AVMC + EP (40 mg/kg/
day)
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that treatment with ethyl pyruvate significantly reduced 
the expression of HMGB1 and inhibited the release of 
HMGB1 in the mice with AVMC, which was accompa-
nied with decreased mortality and myocardial inflam-
mation caused by CVB3 infection. These observations 
supports that ethyl pyruvate protects against AVMC via 
an anti-HMGB1 mechanism.
Previous studies have demonstrated that the pathogenic 
role of HMGB1 depends on the interaction of HMGB1 
with its receptor-RAGE and the activation of downstream 
NF-ΚB pathway (Ulloa and Messmer 2006). The HMGB1/
RAGE/NF-ΚB pathway is closely associated with inflam-
mation in many diseases, such as systemic lupus erythe-
matosus, diabetes, etc. (Sun et al. 2013; Kim et al. 2011). 
Therefore, inhibition of HMGB1-mediated inflamma-
tory pathway has been regarded as a novel strategies for 
anti-HMGB1 (Kang et  al. 2014). Our study showed that 
increase of RAGE in the hearts of AVMC mice was mark-
edly attenuated by ethyl pyruvate treatment, which indi-
cated the inhibition of HMGB1 pathway induced by ethyl 
pyruvate was via the suppression of RAGE. Recently, the 
results from in vivo and vitro studies indicated that ethyl 
pyruvate inhibited NF-ΚB activation by directly modify-
ing p65, and thereby suppressing NF-ΚB DNA binding 
(Han et al. 2005). It was also reported that ethyl pyruvate 
decreased NF-ΚB activity by blockade of degradation of 
IΚBα (Shen et al. 2014). In present study, we found that 
administration of ethyl pyruvate could decrease the lev-
els of phospho-IΚBα, phospho-NF-ΚB p65 and raise 
the expression of IΚBα in the hearts of AVMC mice, 
suggesting that ethyl pyruvate seemed to interfere with 
phosphorylation and degradation of IΚBα, and then 
Fig. 4 Effect of EP on the expression and release of HMGB1. The sham mice and AVMC mice were intraperitoneally administrated with Ringer’s lac-
tate solution (RLS) or 80 mg/kg/day EP from day 5 to day 7 after CVB3 infection. a Real-time PCR analysis of HMGB1 in the hearts. Data were shown 
as mean ± SE from 6 to 12 individual experiments. *P < 0.001 versus Sham + RLS. #P < 0.001 versus Sham + EP. $P < 0.001 versus AVMC + RLS. b 
Immunoblot for analysis on HMGB1 expression in the hearts. The blot is showed in the upper part. The quantification of HMGB1 expression was 
shown in the lower part. Data were shown as mean ± SE from 6 to 12 individual experiments. *P < 0.001 versus Sham + RLS. #P < 0.001 versus 
Sham + EP. $P < 0.001 versus AVMC + RLS. c Immunochemistry for the localization of HMGB1 in the hearts (Left ×200, ×Right ×400). HMGB1 was 
predominantly located in the nuclei of the cells in the hearts of sham mice. However, in the hearts of AVMC mice, HMGB1 was not only positive in 
the nuclei but also positive in the cytoplasm of the cells and extracellular milieu. The black arrows showed abnormal location of HMGB1. d ELISA for 
quantitative analysis of serum HMGB1. Data were shown as mean ± SE from 6 to 12 individual experiments. *P < 0.001 versus Sham + RLS; #P < 0.05 
versus Sham + EP; $P < 0.01 versus AVMC + RLS
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inhibited activation of NF-ΚB. Additionally, NF-ΚB tar-
get cytokines were measured and we observed that ethyl 
pyruvate obviously decreased TNF-α, IL-1β and IL-17 
and raised IL-10 in the hearts and serum of AVMC mice. 
Based on these results, we think that the main mecha-
nism responsible for inhibition of ethyl pyruvate on 
CVB3-induced AVMC may be due to that it suppressed 
HMGB1-mediated RAGE/NF-ΚB pathway.
Fig. 5 Effect of ethyl pyruvate (EP) on the expression of RAGE and NF-ΚB pathway. The sham mice and AVMC mice were intraperitoneally admin-
istrated with Ringer’s lactate solution (RLS) or 80 mg/kg/day EP from day 5 to day 7 post-infection. a Immunoblot for the expression of RAGE, phos-
pho (p)-NF-ΚB p65, NF-ΚB p65, p-IΚBα and I-ΚBα. b–e Quantification of RAGE (b), p-NF-ΚB p65 (c), p-IΚBα (d) and I-ΚBα (e). Data were shown as 
mean ± SE from 6 to 12 individual experiments. *P < 0.01 versus Sham + RLS; #P < 0.05 versus Sham + EP; $P < 0.05 versus AVMC + RLS
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Conclusion
In summary, ethyl pyruvate inhibited CVB3-induced 
AVMC, which is closely associated with the suppression 
of HMGB1/RAGE/NF-κB pathway. This study indicated 
that ethyl pyruvate may be a potential anti-inflammatory 
agent to treat AVMC.
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of TNF-α (a), IL-1β (b), IL-17 (c) and IL-10 (d) in the hearts. Data were shown as mean ± SE from 6 to 12 individual experiments. *P < 0.001 versus 
Sham + RLS; #P < 0.001 versus Sham + EP; $P < 0.01 versus AVMC + RLS. e–h ELISA for quantitative analysis of serum TNF-α, IL-1β, IL-17 and IL-10. 
Data were shown as mean ± SE from 6 to 12 individual experiments. *P < 0.001 versus Sham + RLS; #P < 0.001 versus Sham + EP; $P < 0.01 versus 
AVMC + RLS
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